Fortrea Holdings Appoints Anshul Thakral as New CEO

Fortrea Holdings Inc. ( (FTRE) ) has provided an announcement.

On June 11, 2025, Fortrea Holdings Inc. announced the appointment of Anshul Thakral as the new President and CEO, effective August 4, 2025, succeeding interim CEO Peter M. Neupert, who will remain as chairman of the board. Thakral, with over 20 years of experience in the life sciences sector, aims to focus on executing Fortrea’s transformation plan and enhancing its focus on profitable growth, while overseeing efforts to create additional value for customers, employees, and shareholders.

The most recent analyst rating on (FTRE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Fortrea Holdings Inc. stock, see the FTRE Stock Forecast page.

Spark’s Take on FTRE Stock

According to Spark, TipRanks’ AI Analyst, FTRE is a Neutral.

Fortrea Holdings Inc. faces significant financial challenges, with declining revenue, high leverage, and unprofitability reflected in a negative P/E ratio. While the technical analysis indicates negative momentum, the earnings call suggests some resilience with strong pipeline management and cost reduction efforts. However, operational inefficiencies and financial strain from goodwill impairment are notable risks.

To see Spark’s full report on FTRE stock, click here.

More about Fortrea Holdings Inc.

Fortrea Holdings Inc. is a leading global provider of clinical development solutions to the life sciences industry. The company partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies to drive healthcare innovation and accelerate life-changing therapies to patients. Fortrea offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging three decades of experience across more than 20 therapeutic areas.

Average Trading Volume: 2,991,838

Technical Sentiment Signal: Sell

Current Market Cap: $489.6M

For an in-depth examination of FTRE stock, go to TipRanks’ Stock Analysis page.